Verrica’s YCANTH Expands Its Footprint as Q1 2026 Revenue Grows; Japan Launch Underpins Ex‑U.S. Push

Financial Highlights

The quarterly update from Verrica Pharmaceuticals Inc. (VRCA) shows a US-centric revenue lift that looks almost like a real business waking up from clinical sleep. Total revenue for the first quarter ended March 31, 2026 came in at $5.0 million, with US YCANTH net product revenue accounting for $4.3 million. Management notes this as a 16.2% increase from the prior quarter and a 25.4% rise year over year, a pattern you might expect from a product inching toward stable payer and clinician adoption rather than a one-off launch bump.

In the same breath, Verrica disclosed dispensed applicator units of 15,302 in Q1 2026, up 12.1% sequentially and 51.3% year over year. Cumulatively, more than 100,000 dispensed applicator units have been issued since launch, signaling that the product is becoming a normal, repeat-use item in the molluscum treatment stack—not just a novelty in a high-cost, early-stage rollout.

One notable omission in the press release is any EPS figure, EPS consensus, or other earnings-per-share commentary. In other words, while the revenue cadence is tangible, the typical earnings metrics that some investors track for a biotech/pharma story aren’t part of Verrica’s Q1 2026 narrative. There’s no explicit forecast or guidance update here, either; the document is more focused on revenue mix, run rate, and pipeline milestones than on a formal revenue forecast for 2026 or beyond.

Operational Highlights and strategic moves

Beyond the numbers, Verrica’s narrative emphasizes growth levers in the molluscum space and pipeline progress. A key strategic milestone is the Japan launch of YCANTH (VP-102) through partner Torii Pharmaceutical, marking Verrica’s first ex‑U.S. market expansion. The move is framed as a proof point for the company’s commercialization strategy and the viability of its partner-driven international expansion, even as the domestic market remains the primary revenue engine.

On the development side, Verrica reiterates its ongoing global Phase 3 program for common warts (VP-102). The company reports that more than 50% of the current enrollment target has been achieved in the first trial (COVE-2). A second Phase 3 trial (COVE-3), with sites in the United States and Japan, is expected to be initiated in mid-2026. If successful, the common warts program could unlock a much larger patient population—an implicit revenue enlargement story that investors often weigh alongside current product performance.

In parallel, Verrica notes progress in VP-315, its oncolytic peptide candidate for basal cell carcinoma, with data from Phase 2 generating interest in the dermatology and oncology communities. The company frames this as building optionality—late-stage assets that could extend the company’s addressable market beyond molluscum.

Conference Call, Webcast, and What It Might Mean for the Sector

Verrica has scheduled a conference call and webcast for Tuesday, May 12, 2026, at 4:30 pm ET to discuss the quarter and provide a business update. The call will also be accessible live on the company’s website, in addition to a replay. The availability of a webcast and a clear emphasis on pipeline milestones are consistent with a small-cap biotech navigating the dual realities of ongoing commercialization and the need to fund multi-year clinical programs.

From a sector perspective, the Japan launch via Torii is a reminder that the path to meaningful ex‑US revenue for specialty dermatology products often hinges on partnerships that can navigate local regulatory and distribution landscapes. The COVE-2 enrollment milestone is the kind of near-term data point investors often latch onto; the real question is whether the US/Japan, site mix, and payer acceptance translate into durable, above-trend growth as the base of the molluscum franchise expands. The announced mid-2026 start for COVE-3 adds a potential catalyst, but it also surfaces execution risk around patient recruitment and regulatory timelines in multiple jurisdictions.

With no EPS or explicit revenue forecast disclosed, the story remains a revenue-growth and pipeline‑driven narrative rather than a straight line toward profitability in the near term. For VRCA holders, the key is whether YCANTH’s expansion into Japan can sustain top-line momentum, and whether the common warts program can drive a step change in addressable patients and pricing dynamics. The presence of VP-315 in Phase 2 and potential follow-ons in the pipeline suggests Verrica is trying to diversify sources of value rather than rely solely on molluscum as a single-asset catalyst.

What This Signals for Verrica and Peers

The story here is modest in the near term but potentially consequential in the mid-term. A few takeaways:

• Revenue trajectory vs. earnings: VRCA’s Q1 revenue trajectory is real, but without EPS data or a stated forecast, investors must infer profitability timing from operating leverage and gross margin progression in US YCANTH, plus the contribution from partner markets like Japan.
• International expansion as a value accelerant: The Japan launch expands the company’s total addressable market and tests Verrica’s go-to-market playbook in a more diversified revenue mix.
• Pipeline optionality: VP-315’s Phase 2 progress and the global Phase 3 program for common warts keep Verrica positioned as a platform with multiple potential catalysts. The timing of COVE-3 and the trajectory of enrollment will be watched closely for raised revenue expectations or new patient pool access.
• Sector implications: If Verrica demonstrates durable funding for Phase 3 programs and maintains US revenue growth, peers with similar molluscum or dermatology franchises may experience a re-rating on pipeline maturity and international partnerships rather than on quarterly earnings surprises alone.